Table 1.
Characteristics of the study population
| Overall | |
|---|---|
| (N = 62) | |
| Gender | |
| Female | 41 (66.1%) |
| Male | 20 (32.3%) |
| Missing | 1 (1.6%) |
| Race | |
| White | 48 (77.4%) |
| Black | 12 (19.4%) |
| Other | 1 (1.6%) |
| Missing | 1 (1.6%) |
| Cancer Type | |
| Breast | 23 (37.1%) |
| Lymphoma | 33 (53.2%) |
| Sarcoma | 6 (9.7%) |
| Coronary Artery Disease | |
| No | 58 (93.5%) |
| Yes | 4 (6.5%) |
| Smoking History | |
| No | 42 (67.7%) |
| Yes | 20 (32.3%) |
| Diabetes | |
| No | 52 (83.9%) |
| Yes | 10 (16.1%) |
| Hypertension | |
| No | 40 (64.5%) |
| Yes | 22 (35.5%) |
| Anthracycline | |
| No | 20 (32.3%) |
| Yes | 42 (67.7%) |
| Diuretic | |
| No | 50 (80.6%) |
| Yes | 12 (19.4%) |
| Beta Blocker | |
| No | 58 (93.5%) |
| Yes | 4 (6.5%) |
| ACE Inhibitor | |
| No | 53 (85.5%) |
| Yes | 9 (14.5%) |
| Angiotensin Receptor Blocker | |
| No | 58 (93.5%) |
| Yes | 4 (6.5%) |
| Calcium Channel Blocker | |
| No | 57 (91.9%) |
| Yes | 5 (8.1%) |
| Lipid Lowering Drugs | |
| No | 42 (67.7%) |
| Yes | 20 (32.3%) |
| Baseline IMF, cm2 | |
| Mean (SD) | 9.13 (4.08) |
| Baseline BMI, kg/m2 | |
| Mean (SD) | 30.0 (5.76) |
| Change in EF from Baseline, % | |
| Mean (SD) | −5.12 (8.25) |
| Baseline Systolic BP, mmHg | |
| Mean (SD) | 119 (17.5) |
| Baseline Diastolic BP, mmHg | |
| Mean (SD) | 69.8 (13.5) |